Moreover, the compound was also able to down-regulate MYC target genes, and this might be clinically relevant for DLBCL, in which MYC confers a very poor clinical outcome when co-expressed with the BCL2 protein or when co-translocated with the BCL2 gene [39, 40]. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.